GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

Abstract excerpt

Gliomas are the most common primary tumors of the central nervous system (CNS).Among low-grade gliomas, mitogenactivated protein kinase (MAPK) pathway alterations are frequent and may provide a therapeutic target.Currently, mechanism-of-action based therapeutic approaches outside the MAPK pathway are scarce.However, especially patients with subtotally resected, recurrent or highly malignant tumors may...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to ATP Synthase and ATPases Research
• Share to Cancer, Hypoxia, and Metabolism
• Share to Glioma Diagnosis and Treatment